1α-Hydroxyvitamin D3 inhibits Type II collagen-induced arthritis in rats  by Tsuji, Michiko et al.
FEBS Letters 337 (1994) 248-250 
ELSEVIER 
FEBS 13540 
LETTERS 
la-Hydroxyvitamin D, inhibits Type II collagen-induced arthritis in rats 
Michiko Tsuji”, Katsuyuki Fujii”,*, Toshiaki Nakanob, Yasuho Nishiib 
“Department of Orthopaedic Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi. Minato-ku, Tokyo, 105. Japan 
bResearch Laboratories, Chugai Pharmaceutical Co Ltd, 3-41-8 Takada, Toshima-ku, Tokyo 171. Japan 
Received 15 November 1993: 
Abstract 
The effects of la-hydroxyvitamin D, and 24,25_dihydroxyvitamin D, on Type II collagen-induced arthritis in rats, an experimental model of 
rheumatoid arthritis, were examined. Oral administration of la-hydroxyvitamin D, significantly suppressed the incidence of arthritis and inhibited 
hind paw swelling. The level of anti-Type II collagen antibodies was decreased in the la-hydroxyvitamin D, treated-group. In contrast, 24,25- 
dihydroxyvitamin D,, indomethacin, and gold had no effect on either the incidence of arthritis or the antibody levels. These findings demonstrate 
a beneficial effect of la-hydroxyvitamin D, on Type II collagen-induced arthritis in rats and indicate that it has an antirheumatic effect. 
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1. Introduction 
la-OH-D, is a vitamin D, derivative that is known to 
be a regulator of calcium homeostasis. la-OH-D, is 
transported by a vitamin D-binding protein to the liver 
where it undergoes 25hydroxylation to become 101,25- 
(OH),-D,, a biologically active vitamin D, metabolite 
[l-3]. Specific receptors for lcx,25-(OH),-D, (calcitriol) 
are expressed by peripheral blood monocytes [4] and 
mitogen-activated T lymphocytes [5], and calcitriol is 
also known to be potent in suppressing the proliferation 
and inducing the differentiation of cells in the immune 
system [&9]. 
In 1977, Trentham et al. [lo] reported Type II colla- 
gen-induced arthritis developed in rats, and antibodies 
against autologous Type II collagen were shown to be 
critically involved in the pathogenesis of this type of 
arthritis [ll]. In addition, we recently found that RA 
patients have circulating antibodies against human Type 
II collagen, and that these antibodies frequently appear 
during the early phase of the disease [12,13]. These find- 
ings led us to a special interest in Type II collagen- 
induced arthritis as a model of RA. 
In the present study, we examined the effects of la- 
OH-D3 and 24,25-(OH),-D, on Type II collagen-induced 
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arthritis in comparison with a nonsteroidal anti-inflam- 
matory agent (indomethacin) and gold. 
2. Materials and methods 
2 I. Induction of arthrrtls 
Bovine native Type II collagen (Cosmo Bio. Ltd.) was dissolved m 
5 mM acetic acid at a concentration of 4 mg/ml and was mixed with 
an equal volume of 1 mg/ml muramyl dipeptide (Dai-ichi Pharmaceuti- 
cal Co. Ltd.) in distilled water. The solution was emulsified m an equal 
volume of Freund’s incomplete adjuvant (Difco Laboratories Co. Ltd.) 
at 4°C. Female Lewis rats weighing 150 g were immunized with 1 ml 
of the cold emulsion by intradermal injection mto the back. Animals 
were weighed every 4 days after injection. The volumes of the two hind 
paws were measured by the water displacement method with a hind paw 
volume meter (Muromachi Co. Ltd.), and the mean value for both paws 
was calculated. Results were expressed as the percent increment in paw 
volume relative to that on day 0. 
2.2. Histologrcal observation 
The affected feet were removed at post mortem, fixed m 10% buffered 
formalin, and decalctfied in EDTA in buffered formahn (5.5% w/v). The 
feet were then embedded in paraffin, sectioned, and stained with hema- 
toxyhn and eosin. 
2.3. Assay for an&Type II collagen antibodies 
The anti-Type II collagen antibody level was measured by an ELISA 
using buffered normal rabbit serum as the blocking agent to diminish 
non-specific binding of IgG to the plastic plates as previously described 
[13]. Serum samples were diluted to 1:lOOO for IgG, and I:50 for IgM 
in buffered normal rabbit serum and were added to the plates. The 
second antibody consisted of peroxidase-conjugated rabbit anti-rat IgG 
or IgM (Cooper Biochemical, Cochranville, PA) was diluted to 1:2000 
with 25% buffered normal rabbit serum. A positive standard consisting 
of pooled serum from arthritic Lewis rats was Included in each plate. 
The reactivity of serum with Type II collagen was more than 80% 
inhibited by the antigen. 
2.4. Drug treatment 
Immunized rats were divided into 6 groups of 15 rats each, and drugs 
were given orally on a daily basis from the day of the first immunization. 
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2.5. Statistical analysis 
For continuous variables (i.e. antibody levels), the mean values were 
compared between the groups by Student’s r-test. For dichotomous 
variables (i.e. the incidence of arthritis), the percentages were compared 
between groups. 
3. Results and discussion 
Although some weight loss was observed in CIA rats 
at 3-5 weeks after immunization, there was no significant 
difference in body weight between the control and CIA 
rats after 7 weeks. This finding indicates that rats 
adapted to the inflammatory stress caused by Type II 
collagen injection. Tumor necrosis factor released from 
macrophages may be involved in the manifestation of 
such inflammatory stress, since similar effects of weight 
loss and adaptation were previously reported in rodents 
treated with this cytokine [14]. Drug treatment did not 
affect body weight of CIA rats. 
The overall incidence of arthritis was calculated by 
histological examination of the feet of rats. All rats in the 
untreated group demonstrated inflammatory arthritis 
characterized by the proliferation of synovial lining cells, 
periarticular edema, infiltration of mononuclear cells 
and polymorphonuclear leukocytes, and the destruction 
of bone and articular cartilage by granulation tissue [lo]. 
Administration of la-OH-D, reduced the incidence of 
arthritis to 13.3% (2/15 rats), while the incidence in the 
24,25-(OH),-D,-treated group was 86.7% (13/l 5 rats). 
The hind paw volume of untreated CIA rats increased 
gradually and reached a maximum around 6 weeks after 
immunization (Fig. 1). la-OH-D, significantly inhibited 
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Fig. 1. Effects of la-OH-D, and 24,25-(OH)2-D, on hind paw swelling 
in rats with Type II collagen-induced arthritis. Each value represents 
the mean of 15 rats. Asterisks (*) indicate a significant difference rela- 
tive to the untreated rats (P < 0.01). o = untreated; l = indomethacin 
(5 mg/kg); A = la-OH-D, (0.1 &kg); * = lo-OH-D, (0.25 &kg); 
x = 24.25-(OH)2-D, (10 pg/kg); q = gold (15 mg Au/kg). 
2.C 
1.c 
E 
s 
iii 
r” t 0.0 
4 
z = 
0” 0.08 
0.04 
0.00 
249 
0 20 40 60 
Days after immunization 
Fig. 2. Effects of la-OH-D, and 24,25-(OH)2-D, on anti-Type II colla- 
gen antibody levels. Each value represents the mean of 15 rats. Aster- 
isks (*) indicate a significant difference relative to the untreated rats 
(P < 0.01). (A) Levels of IgG antibody directed against native Type II 
collagen. Serum samples were diluted to 1: 1000 with buffered normal 
rabbit serum. (B) Levels of IgM antibody directed against native Type 
II collagen. Serum samples were diluted to 1:50 with buffered normal 
rabbit serum. o = untreated; l = indomethacin (5 mg/kg); A = la-OH- 
D, (0.1 &kg); A = ICC-OH-D, (0.25,@kg); x = 24,25-(OH)2-D, (lo/@ 
kg); q = gold (15 mg Au/kg). 
paw swelling throughout the experiment at a dose of 
both 0.1 pug and 0.25 &kg. On the other hand, 24,25- 
(OH),-D, had almost no inhibitory effect. Gold and in- 
domethacin were found to inhibit paw swelling to 50% 
and 35% of that in the untreated group, respectively. 
la-OH-D, significantly inhibited all the histopatho- 
logical changes noted in CIA rats, including the prolifer- 
ation of synovial lining cells, periarticular edema and 
destruction of bone and articular cartilage, although a 
small amount of granulation tissue was still observed. 
The level of IgG antibody directed against native Type 
II collagen, which was quantified in sera diluted to 
1: 1000, began to increase just before the onset of arthritis 
at 10-14 days after immunization (Fig. 2). IgM antibody, 
which was quantified in sera diluted to 1:50, appeared 
earlier at 4-7 days after immunization (Fig. 2B). la-OH- 
D, (0.1 pg and 0.25 pg!kg) significantly decreased the 
2.50 
levels of IgG and IgM antibodies (P c 0.01) (Fig. 2A,B). 
In contrast, 24,25-(OH),-D,, gold, and indomethacin 
showed no inhibitory effect on both the IgG and IgM 
antibodies. 
In this study, la-OH-D, was found to inhibit the de- 
velopment of CIA by suppressing anti-Type II collagen 
antibody production, even though it has been reported 
that most of the slowly acting anti-rheumatic drugs (i.e. 
D-penicillamine, levamisole, sulfapyridine, and gold) 
have no beneficial effect on this type of arthritis [15]. 
Indomethacin also inhibited the hind paw swelling and 
histopathological changes, perhaps due to the suppres- 
sion of prostaglandin E, production [16]. However, it 
had no effect on the anti-Type II collagen antibody level. 
The difference between the effects of vitamin D,, in- 
domethacin. and gold on CIA was probably due to dif- 
ferences in their mechanism of action. Vitamin D, is a 
steroid hormone that binds to specific intracellular re- 
ceptors expressed by numerous types of cells, including 
lymphoid cells [17]. Such receptors are not expressed by 
normal resting T and B lymphocytes, but they can be 
demonstrated following activation of these cells. The 
major effect of vitamin D, is on the early stages of T cell 
activation as well as the inhibition of interleukin-2 syn- 
thesis [18]. Therefore, the inhibition of CIA by la-OH- 
D, administration may be primarily due to the suppres- 
sion of T cell proliferation and interleukin-2 synthesis. 
We recently developed an improved ELISA for the 
detection of anti-collagen antibodies in human serum to 
diminish non-specific background interference and pro- 
vide a higher sensitivity [13]. Using this assay system, 
IgG antibodies against native Type II collagen were de- 
tected in 22.7% of the serum samples from 480 patients 
with RA [12]. The antibodies were found to be collagen 
type-specific, showing no reactivity with human Type I 
and Type III collagens. In addition, these anti-Type II 
collagen antibodies appeared at a high incidence (75.4%) 
during the early phase of the disease. 
Thus, the data obtained from the present study using 
CIA rats suggest hat la-OH-D, may have a therapeutic 
value as an immunoregulatory agent in RA patients. 
There is a good possibility that calcitriol, a biologically 
M Tsuj et al. IFEBS Letters 337 (1994) 248750 
active form of la-OH-D,, has an antirheumatic effect 
not only through the suppression of inflammation, but 
also through inhibition of the autoimmune response to 
Type II collagen. 
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